HPV-associated malignancies
Transgene’s clinical research includes HPV-16-positive recurrent or metastatic cancers, with attention to oropharyngeal squamous cell carcinoma and other advanced HPV-related solid tumors such as cervical cancer, vulvar cancer, vaginal cancer, penile cancer, and anal cancer.
- Oropharyngeal squamous cell carcinoma
- Cervical cancer
- Vulvar, vaginal, penile, and anal cancers
The sponsor’s work in this area centers on immunotherapy and virus-associated cancer treatment.
Head and neck cancer
Clinical activity also extends to advanced head and neck squamous-cell carcinoma, including newly diagnosed stage III and stage IV disease in the oral cavity, oropharynx, hypopharynx, and larynx, as well as recurrent or metastatic settings.
- Oral cavity carcinoma
- Oropharyngeal cancer
- Hypopharyngeal and laryngeal cancer
Research in this domain reflects a focus on advanced head and neck oncology and tumor-specific immune therapies.
Non-small cell lung cancer
Transgene funds studies in non-small cell lung cancer across metastatic and advanced disease, including patients with recurrent or progressive lung cancer where immuno-oncology approaches are being explored.
- Advanced NSCLC
- Metastatic lung cancer
- Recurrent lung cancer
This area connects the sponsor’s portfolio with thoracic oncology and checkpoint-based cancer treatment.
Skin and soft tissue cancers
The sponsor is active in melanoma, Merkel cell carcinoma, and metastatic or advanced soft tissue sarcoma, covering aggressive cutaneous and mesenchymal tumors.
- Melanoma
- Merkel cell carcinoma
- Soft tissue sarcoma
These programs align with interest in advanced solid tumors and immune-mediated anti-tumor strategies.
Advanced solid tumors
Additional clinical work includes triple negative breast cancer and other difficult-to-treat advanced solid tumors, broadening the sponsor’s oncology portfolio beyond tumor types linked to specific viral or anatomic targets.
- Triple negative breast cancer
- Advanced solid tumor malignancies
- Metastatic cancer
These studies support exploration of cancer immunotherapy across multiple refractory tumor settings.
